Clovis' gemcitabine lipid vector starts Phase I; GeNO nitric oxide gains orphan drug designation;

> Clovis Oncology has kicked off a Phase I study of Clavis Pharma's CP-4126 (CO-101) in combination with cisplatin in patients with non-small cell lung cancer. CP-4126 uses Clavis Pharma's lipid vector technology to transport gemcitabine into tumor cells to overcome resistance. Press release

> The FDA has granted GeNO orphan drug designation for nitric oxide delivered via the GeNOsyl MVG-2000 delivery system for the treatment of persistent pulmonary hypertension in newborns (PPHN). Press release

> Salix Pharmaceuticals and Alfa Wassermann have signed an agreement giving Salix exclusive rights in North America to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease. Press release

> pH-switchable polymer nanostructures could offer opportunities for controlled release. Abstract

> Doxorubicin-loaded nanoparticles have potential in tumor-targeted chemotherapy. Abstract

> Tonix Pharmaceuticals' sublingual formulation of its fibromyalgia (FM) drug TNX-102 reduces the production of a problematic metabolite. Press release

> The FDA has approved Sanofi's auto-injector that (literally!) talks users through injection, using audio and visual cues. Article

And Finally… Microparticles can delivery oxygen into the bloodstream, so that people can live without breathing. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.